drugset / Trial / NCT04176913
Study of LUCAR-20S in Patients With R/R NHL
Phase 1
Terminated
7 enrolled
The First Affiliated Hospital with Nanjing Medical University
Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC west district; Beijing Boren Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
An open label, single arm Phase I study to evaluate the safety, tolerability, and pharmacokinetics of LUCAR-20S CAR-T cells in relapsed or refractory CD20+ diffuse large B-cell, follicular, mantle cell and small lymphocytic lymphoma.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-12-09
- Completion
- 2021-12-09
Outcome
Outcome not reported
Stopped: “Both the sponsors and collaborator are considering terminating the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-20S | Cell therapy | — | — |